1. Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2)-induced infection, the cause of coronavirus disease 2019 (COVID-19), is characterized by acute clinical pathologies, including various coagulopathies.
2. Recently, a new COVID-19 phenotype has been noted in patients after they have ostensibly recovered from acute COVID-19 symptoms, commonly termed Long COVID/Post-Acute Sequelae of COVID-19 (PASC).
3. This study investigates if the lingering symptoms that individuals with Long COVID/PASC manifest might be due to the presence of persistent circulating plasma microclots that are resistant to fibrinolysis.
This article is generally reliable and trustworthy as it provides evidence for its claims through techniques such as proteomics and fluorescence microscopy. The authors also provide detailed descriptions of their methods and results, which allows readers to assess the validity of their findings. Furthermore, the authors note potential limitations in their study such as sample size and lack of control groups for certain experiments.
However, there are some areas where the article could be improved upon. For example, while the authors discuss potential implications of their findings, they do not provide any concrete recommendations or solutions based on their research. Additionally, while the authors mention possible risks associated with Long COVID/PASC symptoms, they do not explore these risks in depth or provide any further information about them. Finally, while the article does present both sides of an argument fairly equally, it does not explore any counterarguments or alternative explanations for its findings.